Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases.
Company Profile
Industry Classifications
Sector:
Healthcare
Industry:
Biotechnology
NAICS:
Pharmaceutical Preparation Manufacturing (325412)
SIC:
Pharmaceutical and Medicine Industry (3741)
Contact Information
Investor Relations
Andrea Christopher
Executive Director, Corporate Communications & Investor Relations
achristopher@auriniapharma.com
General inquiries can also be sent to
ir@auriniapharma.com
